Kumar Neil 4

What Happened
Neil Kumar, CEO of BridgeBio Pharma, sold a total of 80,000 BridgeBio shares in open‑market/private transactions on June 4–5, 2026. The sales totaled approximately $5,413,286 (average ≈ $67.67/share). Individual tranches ranged from about $65.15 up to $69.51 per share across the reported trades. These were sales (not purchases or option exercises).

Key Details

• Transaction dates: June 4–5, 2026; filing date: June 8, 2026 (Form 4 accession 0001470831-26-000523). Filing appears timely under Section 16 (within required business‑day window).
• Total shares sold: 80,000; approximate proceeds: $5.41 million; weighted average sale price ≈ $67.67 per share.
• Price range: per footnotes, sales occurred across roughly $65.145 to $69.51 per share (footnotes F2–F9 give weighted‑average subranges; detailed per‑price breakdown available upon request).
• 10b5‑1 plan: At least some sales were effected pursuant to a Rule 10b5‑1 plan adopted March 31, 2025 (F1).
• Beneficial ownership disclaimer: The reporting person disclaims beneficial ownership of certain shares except to the extent of any pecuniary interest (F3).
• Transaction code: S = Sale. No purchases or option exercises reported in this filing.

Context
Sales executed under a pre‑arranged 10b5‑1 plan are typically routine and do not necessarily reflect the insider’s short‑term view of the company. Because these were outright sales (not buys or option exercises followed by immediate sale), they are not usually interpreted as a bullish signal. If you want the exact per‑price breakdown or the post‑transaction holdings reported on the full Form 4, that information can be retrieved from the SEC filing or requested from the filer/Commission staff as noted in the footnotes.